1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Hydroxyzine (hydrochloride; pamoate salt) |
| brand | String | Vistaril (pamoate), Atarax (HCl, discontinued in US as brand) |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:Antihistamines|First-generation antihistamine]] • [[:Category:Anxiolytics|Anxiolytic]] • [[:Category:Antipruritics|Antipruritic]] • [[:Category:Sleep aids|Sleep aid (off-label)]] |
| mechanism | String | '"`UNIQ--vote-0000001D-QINU`"' '''QT prolongation''' risk at high doses prompted the FDA's 2015 caution against use in patients with prolonged QT or with concurrent QT-prolonging medicines'"`UNIQ--ref-0000001E-QINU`"'. |
| uses | String | '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"' |
| starting_dose | String | Anxiety: 25-50 mg PO QID. Pruritus: 25 mg PO TID-QID. Insomnia: 25-50 mg PO at bedtime. Pediatric: 50-100 mg/day divided |
| preparations | String | Tablets 10, 25, 50 mg (HCl); capsules 25, 50, 100 mg (pamoate); oral suspension 25 mg/5 mL; injection 25, 50 mg/mL (IM only, never IV) |
| fda_max | String | 400 mg/day theoretical; in practice rarely exceeds 200 mg/day |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral • intramuscular |
| onset | String | 15-30 minutes (oral) |
| duration | String | 4-6 hours |
| halflife | String | 14-25 hours (longer in elderly and hepatic impairment)'"`UNIQ--ref-00000026-QINU`"' |
| bioavailability | String | ~80% (oral)'"`UNIQ--ref-00000027-QINU`"' |
| pregnancy | String | Limited human data; older agent with substantial use experience; some signal for first-trimester exposure but not conclusive.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> |
| legal | String | [[USLegal:Prescription only|Rx-only]] in US. Not a controlled substance, which is a meaningful clinical advantage over the benzodiazepine alternatives for short-term anxiety'"`UNIQ--ref-00000028-QINU`"' |
